Author(s):
Yaser M. AlWorafi, Sanah Hasan, Nageeb M. Hassan, Ahmed A. Gaili
Email(s):
a.gaili@ajman.ac.ae
DOI:
10.5958/0974-360X.2021.00047.0 
Address:
Yaser M. AlWorafi, Sanah Hasan, Nageeb M. Hassan, Ahmed A. Gaili*
Department of Clinical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, UAE.
*Corresponding Author
Published In:
Volume - 14,
Issue - 1,
Year - 2021
ABSTRACT:
Objectives: The objective of the current study was to investigate the pharmacist’s knowledge, attitude, practice and experience towards pharmacovigilance. Methods: A cross-sectional study was conducted among the pharmacist’s in UAE by using a validated self-administered questionnaire. Results: A total of 230 pharmacists were interviewed. However only 185 questionnaires were completed and analyzed. Of the 185 respondents (59.5%) were male. Pharmacist’s age mean was 32.15 ± 6.86 years. Fifty five (29.7%) pharmacists in this study had good knowledge, while 91 (49.2 %) pharmacists had moderate knowledge and 39 (21.1 %) pharmacists had poor knowledge towards pharmacovigilance, ADRs and ADRs reporting. The finding of this study showed that 82 (44.3 %) of the pharmacists were detected and seen ADRs in their practice at least once. A total of 59 ADRs were seen by the pharmacists in this study. The most common ADRs they detected were gastritis (16 times), followed by allergy (12 times), then rash (8 times), anaphylactic shock (two times) and other ADRs (21). However, none of the detected ADRs were reported. The most barriers reported by pharmacists were: lack of knowledge about reporting system. Factors to encourage ADRs reporting were: enhancing awareness about reporting through attending courses or workshops; receiving educational materials and simplification of reporting procedures. Conclusion: Majority of pharmacists in this study had positive attitude towards pharmacovigilance, ADRs and their reporting. Education and training programs are highly recommended to enhance awareness and improve the reporting of ADRs by pharmacists in UAE.
Cite this article:
Yaser M. AlWorafi, Sanah Hasan, Nageeb M. Hassan, Ahmed A. Gaili. Knowledge, Attitude and Experience of Pharmacist in the UAE towards Pharmacovigilance. Research J. Pharm. and Tech. 2021; 14(1):265-269. doi: 10.5958/0974-360X.2021.00047.0
Cite(Electronic):
Yaser M. AlWorafi, Sanah Hasan, Nageeb M. Hassan, Ahmed A. Gaili. Knowledge, Attitude and Experience of Pharmacist in the UAE towards Pharmacovigilance. Research J. Pharm. and Tech. 2021; 14(1):265-269. doi: 10.5958/0974-360X.2021.00047.0 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2021-14-1-47
REFERENCES:
1. Fahmy S. HAAD Pharmacovigilance Launching Programme. Available from: https://www.haad.ae/HAAD/Portals/0/Toxi-Info-Sept.pdf .
2. WHO publications. The importance of pharmacovigilance: safety monitoring of medicinal products. WHO Collaborating Centre for International Drug Monitoring, Geneva, Switzerland; 2002. ISBN 92-4-159015-7.
3. World Health Organization. (2006). The safety of medicines in public health programs: pharmacovigilance, an essential tool. http://www.who.int/medicines/areas/quality_safety/safety_efficacy/Pharmacovigilance_B.pdf
4. Hazell, L., & Shakir, S. A. (2006). Under reporting of adverse drug reactions. Drug Safety, 29(5), 385-396. https://doi.org/10.2165/00002018-200629050-00003
5. Härmark, L., & Van Grootheest, A. C. (2008). Pharmacovigilance: methods, recent developments and future perspectives. European journal of clinical pharmacology, 64(8), 743-752. https://doi.org/10.1007/s00228-008-0475-9
6. World Health Organization. (1972). International drug monitoring: the role of national centres, report of a WHO meeting [held in Geneva from 20 to 25 September 1971]. http://apps.who.int/iris/handle/10665/40968
7. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Adverse drug reactions. BMJ 1998; 316: 1295–1298. https://doi.org/10.1136/bmj.316.7140.1295
8. Einarson TR. Drug-related hospital admissions. Ann Pharmacother 1993; 27: 832–840. https://doi.org/10.1177/106002809302700702
9. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15–19. https://doi.org/10.1136/bmj.329.7456.15
10. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;279(15):1200-1205. https://doi.org/10.1001/jama.279.15.1200
11. Classen, D. C., Pestotnik, S. L., Evans, R. S., Lloyd, J. F., & Burke, J. P. (1997). Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. Jama, 277(4), 301-306. https://doi.org/10.1001/jama.277.4.301
12. Scott HD, Thacher-Renshaw A, Rosenbaum SE, Waters WJ, Green M, Andrews LG, Faich GA. Physician reporting of adverse drug reactions: results of the Rhode Island adverse drug reaction reporting project. Jama. 1990 Apr 4;263(13):1785-8. https://doi.org/10.1001/jama.263.13.1785
13. Cosentino M, Leoni O, Banfi F, Lecchini S, Frigo G. Attitudes to adverse drug reaction reporting by medical practitioners in a Northern Italian district. Pharmacological research. 1997 Feb 1;35(2):85-8. https://doi.org/10.1006/phrs.1996.0138
14. Al-Worafi YM. Comment on:" Pharmacovigilance in the Middle East". Drug safety. 2014 Aug 1;37(8):651. https://doi.org/10.1007/s40264-014-0192-5
15. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2009;32(1):19–31. https://doi.org/10.2165/00002018-200932010-00002
16. Qassim S, Metwaly Z, Shamsain M, Al Hariri Y. Reporting adverse drug reactions: evaluation of knowledge, attitude and practice among community pharmacists in UAE. IOSR Journal of Pharmacy. 2014;22(30):31-40. https://doi.org/10.9790/3013-040417-23
17. Al-Worafi, Y. M., Kassab, Y. W., Alseragi, W. M., Almutairi, M. S., Ahmed, A., Ming, L. C., and Hadi, M. A. (2017). Pharmacovigilance and adverse drug reaction reporting: a perspective of community pharmacists and pharmacy technicians in Sana’a, Yemen. Therapeutics and Clinical Risk Management, 13, 1175. https://doi.org/10.2147/TCRM.S140674
18. Mahmoud MA, Alswaida Y, Alshammari T, Khan TM, Alrasheedy A, Hassali MA, Aljadhey H. Community pharmacists’ knowledge, behaviors and experiences about adverse drug reaction reporting in Saudi Arabia. Saudi pharmaceutical journal. 2014 Nov 1;22(5):411-8. https://doi.org/10.1016/j.jsps.2013.07.005
19. Yaser Mohammed Al-Worafi. (2018) Knowledge, attitude and practice of Yemeni physicians toward pharmacovigilance: a mixed method study. International Journal of Pharmacy and Pharmaceutical Sciences.18 (10) https://doi.org/10.22159/ijpps.2018v10i10.27407
20. Van Grootheest, A. C., Mes, K., & De Jong-Van Den Berg, L. T. W. (2002). Attitudes of community pharmacists in the Netherlands towards adverse drug reaction reporting. International Journal of Pharmacy Practice, 10(4), 267-272. https://doi.org/10.1211/096176702776868460
21. Al-Worafi YM. Pharmacy practice in Yemen. In Pharmacy Practice in Developing Countries 2016 (pp. 267-287). https://doi.org/10.1016/B978-0-12-801714-2.00014-9
22. Qassim S, Metwaly Z, Shamsain M, AlHariri Y. Spontaneous reporting of adverse drug reactions in UAE: obstacles and motivation among community pharmacists. International Journal of Pharmaceutical Sciences and Research. 2014 Oct 1;5(10):4203.
23. Daniel WW. Biostatistics: A Foundation for Analysis in the Health Sciences, 7th edR Wiley. New York. 1999.
24. Bawazir SA. Attitude of community pharmacists in Saudi Arabia towards adverse drug reaction reporting. Saudi Pharm J. 2006;14(1):75–83.
25. Figueiras A, Herdeiro MT, Polónia J, Gestal-Otero JJ. An educational intervention to improve physician reporting of adverse drug reactions: a cluster-randomized controlled trial. Jama. 2006 Sep 6;296(9):1086-93. https://doi.org/10.1001/jama.296.9.1086
26. Herdeiro MT, Polónia J, Gestal-Otero JJ, Figueiras A. Improving the Reporting of Adverse Drug Reactions. Drug safety. 2008 Apr 1;31(4):335-44. https://doi.org/10.2165/00002018-200831040-00007
27. Rajesh R, Vidyasagar S, Varma DM. An educational intervention to assess knowledge attitude practice of pharmacovigilance among health care professionals in an Indian tertiary care teaching hospital. Int J Pharm Tech Res. 2011;3(2):678–92.
28. Pedrós C, Vallano A, Cereza G, Mendoza-Aran G, Agustí A, Aguilera C, Danés I, Vidal X, Arnau JM. An intervention to improve spontaneous adverse drug reaction reporting by hospital physicians. Drug safety. 2009 Jan 1;32(1):77-83. https://doi.org/10.2165/00002018-200932010-00007
29. Herdeiro MT, Ribeiro-Vaz I, Ferreira M, Polónia J, Falcão A, Figueiras A. Workshop-and Telephone-Based Interventions to Improve Adverse Drug Reaction Reporting. Drug safety. 2012 Aug 1;35(8):655-65. https://doi.org/10.2165/11599750-000000000-00000
30. Johansson ML, Brunlöf G, Edward C, Wallerstedt SM. Effects of e-mails containing ADR information and a current case report on ADR reporting rate and quality of reports. European journal of clinical pharmacology. 2009 May 1;65(5):511-4. https://doi.org/10.1007/s00228-008-0603-6